Navigation Links
Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
Date:11/10/2011

SAN DIEGO, Nov. 10, 2011 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the Company's participation at the Lazard Capital Markets 8th Annual Healthcare Conference at the Pierre Hotel in New York City November 15-16, 2011.

Harry F. Hixson, Jr, Ph.D., Chairman and CEO, and Ronald M. Lindsay, Ph.D., Director and EVP of Research and Development, will present on Tuesday, November 15, 2011 beginning at 8:30 a.m. ET, to provide an overview of and update on the Company.  The presentation is expected to last approximately 30 minutes and will be web cast live through the "Investors" section of the Sequenom website at www.sequenom.com.  An audio replay will be available for 30 days following the initial presentation web cast.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

(Logo:

SOURCE Sequenom, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Webcast Alert: Sequenom: Defining the Future of Noninvasive Prenatal Diagnostics
2. SEQUENOM to Hold First Quarter 2009 Financial Results Conference Call on April 30
3. SEQUENOM Announces Launch of MassARRAY Compact 96 System
4. SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
5. Sequenom Appoints Two New Board Members
6. SEQUENOM Announces Partnership With GeneWorks for Sales & Marketing of MassARRAY Systems and Applications in Australia
7. Sequenom to Present at Two Financial Conferences in March
8. Sequenom to Present at Two Financial Conferences in September
9. Sequenom Announces Formation of Ophthalmology Clinical Advisory Board
10. Sequenom Announces Exercise in Full of Underwriters Option to Purchase Additional Shares
11. Sequenom Announces Publication Acceptance of Manuscript From Trisomy 21 R&D Verification Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... 2015 , ... Proove Biosciences, a commercial and research ... genetics and hypertension at the International Academy of Cardiology Annual Scientific ... The event, which boasts an extensive overview of the latest research developments in ...
(Date:8/26/2015)... ... August 26, 2015 , ... Lee Biosolutions, a global biotech ... manufacture of highly valued cardiac markers used in early detection of heart disease ... chemistry has led to the development and commercialization of important cardiac biomarkers used ...
(Date:8/26/2015)... August 26, 2015 Israel Proves Its Place ... 1 st place  Wayerz comes in 5 th ... Israel by venture capital fund JVP, with Chinese consulting ... China , Israel , ... Impressive achievement for the Israeli representatives in the final ...
(Date:8/26/2015)... (PRWEB) , ... August 26, 2015 , ... PRC ... to develop new business relationships with local sponsors in southern California. The Clinical Trial ... their drug development processes and regulatory pathways., , Stem ...
Breaking Biology Technology:Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... Calif., May 12 USGI Medical, Inc. (USGI),the ... company has,licensed its incisionless surgery technology to Intuitive ... Financial terms of the deal,were not disclosed., ... development,including their intellectual property," said Gary Guthart, president ...
... N.J., May 12 Synvista Therapeutics,Inc. (Amex: ... with the,appointment of David C. Tantillo as Senior ... today, Mr. Tantillo will be responsible,for planning and ... expects commercial launch of this,product in mid- 2009., ...
... PARSIPPANY, N.J., May 12 Forest,Laboratories, Inc. ... company, and,Daiichi Sankyo, Inc. today announced that ... (amlodipine and olmesartan medoxomil),Daiichi Sankyo,s fixed-dose combination ... besylate and the angiotensin receptor,blocker olmesartan medoxomil. ...
Cached Biology Technology:USGI Medical Licenses Incisionless Surgery Technology to Intuitive Surgical 2USGI Medical Licenses Incisionless Surgery Technology to Intuitive Surgical 3Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales 2Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales 3Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales 4Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement 2Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement 3Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement 4
(Date:8/18/2015)... , Aug. 17, 2015 Research ... addition of the "Global Biometric Authentication & ... - Estimation & Forecast, 2015-2020" report to ... authentication and identification systems market is expected to ... 2015 to 2020 and generate over $25 billion ...
(Date:8/12/2015)... MINNETONKA, Minn. , Aug. 12, 2015   ... that supports the entire spectrum of clinical research, is ... ™ , the company,s comprehensive SaaS-based eClinical technology platform, ... growth during the first two quarters of 2015.   ... and second largest quarters measured by contract value sold ...
(Date:8/12/2015)... 12, 2015  New research unveiled at Black ... phones to steal users, fingerprints. Information released today ... fingerprint scanners on mobile devices, making the security ... biometrics on mobile devices, HYPR Corp. recently released ... authentication systems with strong cryptographic security. More information ...
Breaking Biology News(10 mins):Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2MedNet Solutions Experiences Explosive Corporate Growth 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3
... An international consortium of researchers led by Universitat ... patients and studies the clinical impact of the mutations. ... the origins and world distribution of some of the ... in Europe thousands of years ago and later migrated ...
... by Innsbruck University Botanic Garden, with support from ... a practical, one-year, continual professional development (CPD) course ... countries. Its focus on inquiry-based science education (IBSE) ... that IBSE methods are more effective than current ...
... biofuels produced from crop biomass as an environmentally ... questions whether the potential climate benefit of sugarcane ... management are considered. Scientists examined the ... greenhouse gas emissions. They found that land use ...
Cached Biology News:New advances in genetic studies of Fanconi anemia patients 2Hands-on learning turns children's minds on to science 2
... Tissue Arrays contain 60 rabbit tissue samples arrayed ... 4 unstained slides and 1 hematoxylin and eosin ... contains 15 different tissues from 4 rabbit organisms, ... slide. Each tissue sample (or core) is 1.5 ...
... offers custom peptide synthesis with a wide variety ... fit your research needs. Purity: ... 2mg-1g Sequence Length: Up ... Fluorescein, N-acetylation, C-amidation, phosphorylation, D-amino acids, MAPs, KLH/BSA ...
... Antigen sequence: H-Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH 2 ... our corresponding peptide and ... 5 I-labelled peptide, ... (H-1470) and ([ 1 ...
... enables you to identify over 150 ... distinguish protein isoforms, protein subsets, and ... visualize peptide-protein associations and relationships easily. ... identification and relative protein expression analysis ...
Biology Products: